Canadian Journal of Gastroenterology and Hepatology最新文献

筛选
英文 中文
Impact of Immunotherapies on SARS-CoV-2-Infections and Other Respiratory Tract Infections during the COVID-19 Winter Season in IBD Patients. COVID-19冬季期间免疫疗法对IBD患者SARS-CoV-2感染和其他呼吸道感染的影响
IF 2.7 4区 医学
Canadian Journal of Gastroenterology and Hepatology Pub Date : 2022-08-24 eCollection Date: 2022-01-01 DOI: 10.1155/2022/3469789
Constanze Heike Waggershauser, Cornelia Tillack-Schreiber, Paul Weyh, Eckard Alt, Thorsten Siegmund, Christine Berchthold-Benchieb, Daniel Szokodi, Fabian Schnitzler, Thomas Ochsenkühn
{"title":"Impact of Immunotherapies on SARS-CoV-2-Infections and Other Respiratory Tract Infections during the COVID-19 Winter Season in IBD Patients.","authors":"Constanze Heike Waggershauser, Cornelia Tillack-Schreiber, Paul Weyh, Eckard Alt, Thorsten Siegmund, Christine Berchthold-Benchieb, Daniel Szokodi, Fabian Schnitzler, Thomas Ochsenkühn","doi":"10.1155/2022/3469789","DOIUrl":"10.1155/2022/3469789","url":null,"abstract":"<p><strong>Background: </strong>COVID-19 represents one of the most significant medical problems of our time.</p><p><strong>Aims: </strong>This study is focused on the question whether patients with inflammatory bowel disease (IBD) who receive immunotherapies are more vulnerable to respiratory tract infections and SARS-CoV-2 infections in comparison to medical staff, as a cohort with an increased infection risk, and to the general population in a COVID-19 hotspot.</p><p><strong>Methods: </strong>We analysed data regarding respiratory tract infections that were collected in our IBD registry and compared them with corresponding data from medical employees in our associated Isarklinikum hospital and from the healthy general population in Munich, Germany, over the same time frame in April and June 2020. Patients were tested for SARS-CoV-2 immunoglobulins (Ig).</p><p><strong>Results: </strong>Symptoms of respiratory tract infections occurred equally frequent in IBD patients with immunotherapies as compared to those without. Older age (>49 years), TNF-inhibitor, and ustekinumab treatment showed a significantly protective role in preventing respiratory tract symptomatic COVID-19 infections that occurred in 0.45% of all our 1.091 IBD patients. Of those, 1.8% were positive for SARS-CoV-2 Ig, identically to the general population of Munich with also 1.8% positivity. Whilst more than 3% of all COVID-19 subjects of the general population died during the first wave, none of our IBD patients died or needed referral to the ICU or oxygen treatment.</p><p><strong>Conclusions: </strong>In our study, IBD patients are as susceptible to respiratory tract infections or SARS-CoV-2 as the normal population. There is no evidence of an association between IBD therapies and increased risk of COVID-19. Interestingly, a reduced rate of COVID-19 deaths in IBD patients, the majority on immunomodulator therapy, was observed, compared to the general population. Therefore, no evidence was found to suggest that IBD medication should be withheld, and adherence should be encouraged to prevent flares. In addition to older age (>49 years), TNF inhibitors and ustekinumab show a protective role in preventing respiratory tract infections. In addition, these results add to the growing evidence that supports further investigation of TNF inhibitors as a possible treatment in the early course of severe COVID-19.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":" ","pages":"3469789"},"PeriodicalIF":2.7,"publicationDate":"2022-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40346739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-Term Survival and Risk Factors in Patients with Hepatitis B-Related Hepatocellular Carcinoma: A Real-World Study. 乙型肝炎相关肝细胞癌患者的长期生存和危险因素:一项真实世界研究
IF 2.7 4区 医学
Canadian Journal of Gastroenterology and Hepatology Pub Date : 2022-08-23 eCollection Date: 2022-01-01 DOI: 10.1155/2022/7750140
Yu Zhu, Ling-Ling Gu, Fa-Biao Zhang, Guo-Qun Zheng, Ting Chen, Wei-Dong Jia
{"title":"Long-Term Survival and Risk Factors in Patients with Hepatitis B-Related Hepatocellular Carcinoma: A Real-World Study.","authors":"Yu Zhu,&nbsp;Ling-Ling Gu,&nbsp;Fa-Biao Zhang,&nbsp;Guo-Qun Zheng,&nbsp;Ting Chen,&nbsp;Wei-Dong Jia","doi":"10.1155/2022/7750140","DOIUrl":"https://doi.org/10.1155/2022/7750140","url":null,"abstract":"<p><p>A retrospective cohort study was conducted to collect 465 patients with hepatitis B-related hepatocellular carcinoma who had undergone radical hepatectomy from January 1, 2012, to August 31, 2018, at the First Affiliated Hospital of the University of Science and Technology of China. The clinical, pathological, and follow-up information was collected to compare the basic characteristics of death and nondeath after radical resection. Kaplan-Meier curves were used for survival analysis and male and female subgroup analysis. The multivariate Cox proportional-hazards regression model was used to analyze independent risk factors related to postoperative death. Of the 465 patients with radical resection of hepatitis B-related hepatocellular carcinoma, 132 died, and 1-, 3-, and 5-year cumulative survival rates after operation were 92.1%, 78%, and 64%, respectively. In the male and female subgroup, 115 and 17 patients died, respectively. The 1-, 3-, and 5-year cumulative survival rates were 92.6%, 77.0%, and 62.6%, respectively, in men, and 89.6%, 78.8%, and 70.2%, respectively, in women. Multivariate Cox proportional-hazards regression analysis showed that microvascular invasion (MVI), Edmondson III/IV, BCLC stage B, and total bilirubin (TB) > 20.5 <i>μ</i>mol/L were independent risk factors in patients with hepatitis B-related hepatocellular carcinoma after radical hepatectomy.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":" ","pages":"7750140"},"PeriodicalIF":2.7,"publicationDate":"2022-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40342198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma. 药物洗脱珠载雷曲塞经动脉化疗栓塞治疗不可切除或复发性肝癌的临床疗效。
IF 2.7 4区 医学
Canadian Journal of Gastroenterology and Hepatology Pub Date : 2022-08-23 eCollection Date: 2022-01-01 DOI: 10.1155/2022/2602121
Yonghua Bi, Dechao Jiao, Jianzhuang Ren, Xinwei Han
{"title":"Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.","authors":"Yonghua Bi,&nbsp;Dechao Jiao,&nbsp;Jianzhuang Ren,&nbsp;Xinwei Han","doi":"10.1155/2022/2602121","DOIUrl":"https://doi.org/10.1155/2022/2602121","url":null,"abstract":"<p><strong>Objectives: </strong>Although raltitrexed shows therapeutic effects in many types of malignant tumors, the therapeutic effects and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) loaded with raltitrexed for the treatment of hepatocellular carcinoma (HCC) are rare. This study aimed to investigate the safety and efficacy of DEB-TACE with raltitrexed-loaded CalliSpheres beads (CB) in patients with unresectable or recurrent HCC.</p><p><strong>Methods: </strong>Between May 2018 and October 2021, 41 patients with unresectable or recurrent HCC treated by DEB-TACE loaded with raltitrexed were retrospectively enrolled. The primary end points were overall survival and progression-free survival. The response evaluation criteria in solid tumors (RECIST) criteria and modified RECIST criteria (mRECIST) were used to assess the tumor response after the DEB-TACE procedure.</p><p><strong>Results: </strong>A total of 79 DEB-TACE procedures were successfully performed, and the technical success rate was 100%. The overall response rate and disease control rate assessed by mRECIST criteria were 76.9% and 88.5%, 62.5% and 70.8%, and 35.3% and 47.1%, respectively, at 1, 3, and 6 months postprocedure. The mean progression-free survival and overall survival were 21.6 ± 3.6 and 43.7 ± 5.8 months, respectively. The 6-, 24-, and 36-month overall survival rates were 86.8%, 62.7%, and 57.1%, respectively. Minor complications were observed in 21 patients (51.2%), with no treatment-related mortality or severe adverse events. The most common treatment-related complications were abdominal pain (48.8%) and nausea (29.3%).</p><p><strong>Conclusion: </strong>DEB-TACE with raltitrexed-loaded CB suggests a feasible, safe, and efficacious palliative regimen in unresectable or recurrent HCC patients.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":" ","pages":"2602121"},"PeriodicalIF":2.7,"publicationDate":"2022-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40343666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The Feasibility and Safety of the Clip-and-Snare Method with a Prelooping Technique for Gastric Submucosal Tumors Removal: A Single-Center Experience (with Video). 夹圈套法与预环技术用于胃粘膜下肿瘤切除的可行性和安全性:单中心经验(带视频)。
IF 2.7 4区 医学
Canadian Journal of Gastroenterology and Hepatology Pub Date : 2022-08-17 eCollection Date: 2022-01-01 DOI: 10.1155/2022/7957877
Qi Tang, Rui-Yue Shi, Jun Yao, Li-Sheng Wang, De-Feng Li
{"title":"The Feasibility and Safety of the Clip-and-Snare Method with a Prelooping Technique for Gastric Submucosal Tumors Removal: A Single-Center Experience (with Video).","authors":"Qi Tang,&nbsp;Rui-Yue Shi,&nbsp;Jun Yao,&nbsp;Li-Sheng Wang,&nbsp;De-Feng Li","doi":"10.1155/2022/7957877","DOIUrl":"https://doi.org/10.1155/2022/7957877","url":null,"abstract":"<p><strong>Aim: </strong>This study compared the efficacy and safety of endoscopic submucosal dissection (ESD) combined with clip-and-snare method and a prelooping technique (CSM-PLT) with ESD alone for the treatment of gastric submucosal tumors (gSMTs).</p><p><strong>Methods: </strong>We retrospectively enrolled a matched group of 86 patients who received ESD combined with CSM-PLT or ESD alone from July 2010 to July 2020. The primary outcomes included complete resection, en bloc resection, and R0 resection.</p><p><strong>Results: </strong>Eighty-six patients with gSMTs were enrolled in ESD combined with CSM-PLT group and ESD group, respectively. There were no significant differences in gender, age, tumor size, tumor location, and tumor origin between the two groups. The complete resection, en bloc resection, and R0 resection rates were comparable between two groups (<i>P</i>=1, <i>P</i>=0.31, and <i>P</i>=0.25, respectively). There were no significant differences in terms of hospital stays, hospitalization cost, postoperative complications, and residual rate (<i>P</i>=0.42, <i>P</i>=0.74, <i>P</i>=0.65, and <i>P</i>=1, respectively) between the two groups. However, the ESD combined with CSM-PLT was associated with a shorter procedure duration and fewer intraoperative complications (<i>P</i> < 0.001 and <i>P</i>=0.024, respectively). In addition, the incidence of intraoperative bleeding in ESD combined with CSM-PLT group was significantly lower than that in ESD group (<i>P</i>=0.04).</p><p><strong>Conclusion: </strong>Both ESD combined with CSM-PLT and ESD were effective and safe modalities for the treatment of gSMTs. However, ESD combined with CSM-PLT was associated with a shorter procedure duration and fewer intraoperative complications.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":" ","pages":"7957877"},"PeriodicalIF":2.7,"publicationDate":"2022-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33443249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of Overlap Gastroduodenostomy in Billroth I Anastomosis after Totally Laparoscopic Distal Gastrectomy for Gastric Cancer. 胃十二指肠重叠吻合术在腹腔镜胃癌远端切除术后Billroth I型吻合中的应用。
IF 2.7 4区 医学
Canadian Journal of Gastroenterology and Hepatology Pub Date : 2022-08-12 eCollection Date: 2022-01-01 DOI: 10.1155/2022/9094934
Guojun Chen, Wenhuan Li, Weihua Yu, Dong Cen, Xianfa Wang, Peng Luo, Jiafei Yan, Guofu Chen, Yiping Zhu, Linhua Zhu
{"title":"Application of Overlap Gastroduodenostomy in Billroth I Anastomosis after Totally Laparoscopic Distal Gastrectomy for Gastric Cancer.","authors":"Guojun Chen,&nbsp;Wenhuan Li,&nbsp;Weihua Yu,&nbsp;Dong Cen,&nbsp;Xianfa Wang,&nbsp;Peng Luo,&nbsp;Jiafei Yan,&nbsp;Guofu Chen,&nbsp;Yiping Zhu,&nbsp;Linhua Zhu","doi":"10.1155/2022/9094934","DOIUrl":"https://doi.org/10.1155/2022/9094934","url":null,"abstract":"<p><p>Delta-shaped gastroduodenostomy (DSGD) and overlap gastroduodenostomy (OGD) are the two most widely used intracorporeal Billroth I anastomosis methods after distal gastrectomy. In this study, we compared the short-term outcomes of DSGD and OGD in total laparoscopic distal gastrectomy (TLDG). In a retrospective cohort study, we examined 92 gastric cancer patients who underwent TLDG performed by the same surgeon between January 2014 and June 2018. All patients underwent Billroth I reconstruction (OGD, <i>n</i> = 45; DSGD, <i>n</i> = 47) and D2 lymph node dissection. We retrospectively reviewed the surgical outcomes, clinical pathological results, and endoscopy results. Laparoscopic surgery was successfully performed in both groups without conversion to open surgery. The demographic and clinical characteristics were similar between the two groups (<i>P</i> > 0.05). There were no significant differences between the two groups in operation time (158.9 ± 13.6 min vs. 158.8 ± 14.8 min, <i>P</i>=0.955), anastomotic time (19.4 ± 3.0 min vs. 18.8 ± 2.9 min, <i>P</i>=0.354), intraoperative blood loss (88.9 ± 25.4 mL vs. 83.7 ± 24.3 mL, <i>P</i>=0.321), number of lymph node dissections (31.0 ± 7.1 vs. 29.2 ± 7.5, <i>P</i>=0.229), length of hospital stay (8.8 ± 2.7 days vs. 9.1 ± 3.0 days, <i>P</i>=0.636), fluid intake time (3.1 ± 0.7 days vs. 3.2 ± 0.7 days, <i>P</i>=0.914), and morbidity of postoperative complications (6.7% [3/45] vs. 10.6% [5/47], <i>P</i>=0.499). Endoscopy performed 6 months postoperatively showed that the residual food (<i>P</i>=0.033), gastritis (<i>P</i>=0.029), and bile (<i>P</i>=0.022) classification score significantly decreased in the OGD group, and there were no significant differences 12 months postoperatively. OGD is a safe and effective reconstruction technique with comparable postoperative surgical outcomes and endoscopy results when compared with those of DSGD.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":" ","pages":"9094934"},"PeriodicalIF":2.7,"publicationDate":"2022-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391180/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40432107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Insulin Resistance Markers to Detect Nonalcoholic Fatty Liver Disease in a Male Hispanic Population. 在西班牙裔男性人群中检测非酒精性脂肪肝的胰岛素抵抗标志物
IF 2.7 4区 医学
Canadian Journal of Gastroenterology and Hepatology Pub Date : 2022-08-03 eCollection Date: 2022-01-01 DOI: 10.1155/2022/1782221
Maritza Pérez-Mayorga, Jose P Lopez-Lopez, Maria A Chacon-Manosalva, Maria G Castillo, Johanna Otero, Daniel Martinez-Bello, Diego Gomez-Arbelaez, Daniel D Cohen, Patricio Lopez-Jaramillo
{"title":"Insulin Resistance Markers to Detect Nonalcoholic Fatty Liver Disease in a Male Hispanic Population.","authors":"Maritza Pérez-Mayorga,&nbsp;Jose P Lopez-Lopez,&nbsp;Maria A Chacon-Manosalva,&nbsp;Maria G Castillo,&nbsp;Johanna Otero,&nbsp;Daniel Martinez-Bello,&nbsp;Diego Gomez-Arbelaez,&nbsp;Daniel D Cohen,&nbsp;Patricio Lopez-Jaramillo","doi":"10.1155/2022/1782221","DOIUrl":"https://doi.org/10.1155/2022/1782221","url":null,"abstract":"<p><strong>Background: </strong>Nonalcoholic fatty liver disease (NAFLD) is one of the leading causes of chronic liver disease and is closely associated with cardiometabolic disorders, being insulin resistance (IR) the common pathogenic mechanism. The triglycerides/glucose (TyG) index and triglycerides/HDL-c (TG/HDL) ratio are markers correlated with IR. We compared the capacity of these two indexes, alongside IR, to detect NAFLD.</p><p><strong>Methods: </strong>In a cross-sectional cohort study, we examined 263 active military personnel from the Colombian Air Force, aged between 29 and 54 years. Anthropometric measurements and biochemical determinations (glycemia, lipid profile, and insulin) were obtained, and ultrasound studies were performed to evaluate the presence of NAFLD. HOMA-IR index was calculated as (fasting insulin (<i>µ</i>IU/mL) × fasting glucose (mmol/L)/22.5), the TyG index as Ln (triglycerides (mg/dL) × fasting glucose (mg/dL)/2), and the TG/HDL ratio as (triglycerides (mg/dL)/HDL-c (mg/dL)).</p><p><strong>Results: </strong>NAFLD ultrasound criteria were met in 70 individuals (26.6%). Subjects with NAFLD had significantly higher values of HOMA-IR (2.55 ± 1.36 vs. 1.51 ± 0.91), TyG (9.17 ± 0.53 vs. 8.7 ± 0.51), and TG/HDL (6.6 ± 4.54 vs. 3.52 ± 2.32) compared to those without NAFLD (<i>p</i> < 0.001). A TyG cutoff point of 8.92 showed an AUC of 0.731, while cutoff points of 3.83 for TG/HDL and 1.68 for HOMA-IR showed an AUC of 0.766 and 0.781, respectively.</p><p><strong>Conclusion: </strong>Our study shows that novel and lower-cost markers of IR are useful for detecting NALFD, with a performance comparable to the HOMA-IR index. These markers should be used as the first step when screening patients for NAFLD.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":" ","pages":"1782221"},"PeriodicalIF":2.7,"publicationDate":"2022-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365587/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40614108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biologic Agents in Crohn's Patients Reduce CD4+ T Cells Activation and Are Inversely Related to Treg Cells. 克罗恩病患者的生物制剂降低CD4+ T细胞活化,并与Treg细胞呈负相关。
IF 2.7 4区 医学
Canadian Journal of Gastroenterology and Hepatology Pub Date : 2022-07-31 eCollection Date: 2022-01-01 DOI: 10.1155/2022/1307159
Eliane Aparecida Rosseto-Welter, Leticia D'argenio-Garcia, Filipa Blasco Tavares Pereira Lopes, Ana Eduarda Zulim Carvalho, Fernando Flaquer, Vanessa Severo-Lemos, Claudia Concer Viero Nora, Flavio Steinwurz, Lucas Pires Garcia Oliveria, Thiago Aloia, Luiz Vicente Rizzo, Cristóvão Luis Pitangueira Mangueira, Karina Inacio Carvalho
{"title":"Biologic Agents in Crohn's Patients Reduce CD4<sup>+</sup> T Cells Activation and Are Inversely Related to Treg Cells.","authors":"Eliane Aparecida Rosseto-Welter,&nbsp;Leticia D'argenio-Garcia,&nbsp;Filipa Blasco Tavares Pereira Lopes,&nbsp;Ana Eduarda Zulim Carvalho,&nbsp;Fernando Flaquer,&nbsp;Vanessa Severo-Lemos,&nbsp;Claudia Concer Viero Nora,&nbsp;Flavio Steinwurz,&nbsp;Lucas Pires Garcia Oliveria,&nbsp;Thiago Aloia,&nbsp;Luiz Vicente Rizzo,&nbsp;Cristóvão Luis Pitangueira Mangueira,&nbsp;Karina Inacio Carvalho","doi":"10.1155/2022/1307159","DOIUrl":"https://doi.org/10.1155/2022/1307159","url":null,"abstract":"<p><p>Crohn's disease (CD) is a chronic inflammatory disease with a complex interface of broad factors. There are two main treatments for Chron's disease: biological therapy and nonbiological therapy. Biological agent therapy (e.g., anti-TNF) is the most frequently prescribed treatment; however, it is not universally accessible. In fact, in Brazil, many patients are only given the option of receiving nonbiological therapy. This approach prolongs the subsequent clinical relapse; however, this procedure could be implicated in the immune response and enhance disease severity. Our purpose was to assess the effects of different treatments on CD4<sup>+</sup> T cells in a cohort of patients with Crohn's disease compared with healthy individuals. To examine the immune status in a Brazilian cohort, we analyzed CD4<sup>+</sup> T cells, activation status, cytokine production, and Treg cells in blood of Crohn's patients. Patients that underwent biological therapy can recover the percentage of CD4<sup>+</sup>CD73<sup>+</sup> T cells, decrease the CD4<sup>+</sup> T cell activation/effector functions, and maintain the peripheral percentage of regulatory T cells. These results show that anti-TNF agents can improve CD4<sup>+</sup> T cell subsets, thereby inducing Crohn's patients to relapse and remission rates.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":" ","pages":"1307159"},"PeriodicalIF":2.7,"publicationDate":"2022-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40704170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Pretransplant Evaluation and Liver Transplantation Outcome in PBC Patients. PBC 患者移植前评估和肝移植结果
IF 2.7 4区 医学
Canadian Journal of Gastroenterology and Hepatology Pub Date : 2022-07-22 eCollection Date: 2022-01-01 DOI: 10.1155/2022/7831165
Maja Mijic, Ivona Saric, Bozena Delija, Milos Lalovac, Nikola Sobocan, Eva Radetic, Dora Martincevic, Tajana Filipec Kanizaj
{"title":"Pretransplant Evaluation and Liver Transplantation Outcome in PBC Patients.","authors":"Maja Mijic, Ivona Saric, Bozena Delija, Milos Lalovac, Nikola Sobocan, Eva Radetic, Dora Martincevic, Tajana Filipec Kanizaj","doi":"10.1155/2022/7831165","DOIUrl":"10.1155/2022/7831165","url":null,"abstract":"<p><p>Primary biliary cholangitis (PBC) is an autoimmune chronic cholestatic liver disease characterized by progressive cholangiocyte and bile duct destruction leading to fibrosis and finally to liver cirrhosis. The presence of disease-specific serological antimitochondrial antibody (AMA) together with elevated alkaline phosphatase (ALP) as a biomarker of cholestasis is sufficient for diagnosis. Ursodeoxycholic acid (UDCA) is the first treatment option for PBC. Up to 40% of patients have an incomplete response to therapy, and over time disease progresses to liver cirrhosis. Several risk scores are proposed for better evaluation of patients before and during treatment to stratify patients at increased risk of disease progression. GLOBE score and UK PBC risk score are used for the evaluation of UDCA treatment and Mayo risk score for transplant-free survival. Liver transplantation (LT) is the only treatment option for end-stage liver disease. More than 10 years after LT, 40% of patients experience recurrence of the disease. A liver biopsy is required to establish rPBC (recurrent primary biliary cholangitis). The only treatment option for rPBC is UDCA, and data show biochemical and clinical improvement, plus potential beneficial effects for use after transplantation for the prevention of rPBC development. Additional studies are required to assess the full impact of rPBC on graft and recipient survival and for treatment options for rPBC.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":" ","pages":"7831165"},"PeriodicalIF":2.7,"publicationDate":"2022-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9337972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40658130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ERCP-Related Adverse Events in Primary Sclerosing Cholangitis: A Systematic Review and Meta-Analysis. 原发性硬化性胆管炎的 ERCP 相关不良事件:系统回顾与元分析》。
IF 2.7 4区 医学
Canadian Journal of Gastroenterology and Hepatology Pub Date : 2022-07-21 eCollection Date: 2022-01-01 DOI: 10.1155/2022/2372257
Navneet Natt, Faith Michael, Hope Michael, Sacha Dubois, Ahmed Al Mazrou'i
{"title":"ERCP-Related Adverse Events in Primary Sclerosing Cholangitis: A Systematic Review and Meta-Analysis.","authors":"Navneet Natt, Faith Michael, Hope Michael, Sacha Dubois, Ahmed Al Mazrou'i","doi":"10.1155/2022/2372257","DOIUrl":"10.1155/2022/2372257","url":null,"abstract":"<p><strong>Background and aims: </strong>While endoscopic retrograde cholangiopancreatography (ERCP) is a valuable diagnostic and therapeutic tool in primary sclerosing cholangitis (PSC), there is conflicting data on associated adverse events. The aims of this systematic review and meta-analysis are to (1) compare ERCP-related adverse events in patients with and without PSC and (2) determine risk factors for ERCP-related adverse events in PSC.</p><p><strong>Methods: </strong>Embase, PubMed, and CENTRAL were searched between January 1, 2000, and May 12, 2021. Eligible studies included adults with PSC undergoing ERCP and reported at least one ERCP-related adverse event (cholangitis, pancreatitis, bleeding, and perforation) or an associated risk factor. The risk of bias was assessed with the Newcastle-Ottawa scale and Cochrane Risk of Bias 2. Raw event rates were used to calculate odds ratios (ORs) and then pooled using random-effects models.</p><p><strong>Results: </strong>Twenty studies met eligibility criteria, of which four were included in a meta-analysis comparing post-ERCP adverse events in patients with PSC (<i>n</i> = 715) to those without PSC (<i>n</i> = 9979). We found a significant threefold increase in the 30-day odds of cholangitis in PSC compared to those without (OR 3.263, 95% CI 1.076-9.896; <i>p</i>=0.037). However, there were no significant differences in post-ERCP pancreatitis (PEP), bleeding, or perforation. Due to limitations in primary data, only risk factors contributing to PEP could be analyzed. Accidental passage of the guidewire into the pancreatic duct (OR 7.444, 95% CI 3.328-16.651; <i>p</i> < 0.001; <i>I</i> <sup>2</sup> = 65.0%) and biliary sphincterotomy (OR 4.802, 95% CI 1.916-12.033; <i>p</i>=0.001; <i>I</i> <sup>2</sup> = 73.1%) were associated with higher odds of PEP in a second meta-analysis including five studies.</p><p><strong>Conclusions: </strong>In the context of limited comparative data and heterogeneity, PSC patients undergoing ERCP have higher odds of cholangitis despite the majority receiving antibiotics. Additionally, accidental wire passage and biliary sphincterotomy increased the odds of PEP. Future studies on ERCP-related risks and preventive strategies are needed.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":" ","pages":"2372257"},"PeriodicalIF":2.7,"publicationDate":"2022-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334029/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40658129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Delineating Molecular Subtypes through Gene Set Variation Analysis Confers Therapeutic and Prognostic Capability in Gastric Cancer. 通过基因集变异分析描绘分子亚型赋予胃癌的治疗和预后能力。
IF 2.7 4区 医学
Canadian Journal of Gastroenterology and Hepatology Pub Date : 2022-07-15 eCollection Date: 2022-01-01 DOI: 10.1155/2022/5415758
Yuzhang Zhu, Ting Sun, Lei Zhang, Faming Fei, Yi Bao, Zhenzhen Gao
{"title":"Delineating Molecular Subtypes through Gene Set Variation Analysis Confers Therapeutic and Prognostic Capability in Gastric Cancer.","authors":"Yuzhang Zhu,&nbsp;Ting Sun,&nbsp;Lei Zhang,&nbsp;Faming Fei,&nbsp;Yi Bao,&nbsp;Zhenzhen Gao","doi":"10.1155/2022/5415758","DOIUrl":"https://doi.org/10.1155/2022/5415758","url":null,"abstract":"<p><p>To claim the features of nontumor tissue in gastric cancer patients, especially in those who have undergone gastrectomy, and to identify the molecular subtypes, we collected the immunogenic and hallmark gene sets from gene set enrichment analysis. The activity changes of these gene sets between tumor (375) and nontumor (32) tissues acquired from the Cancer Genome Atlas (TCGA-STAD) were calculated, and the novel molecular subtypes were delineated. Subsequently, prognostic gene sets were determined using least absolute shrinkage and selection operator (lasso) regression prognostic method. In addition, functional analysis was conducted. Totally, three subtypes were constructed in the present study, and there were differences in survival among three groups. Functional analysis showed genes from normal gene set were related to cell adhesion, and genes from tumor gene set were associated with focal adhesion, PI3K-Akt signaling pathway, regulation of actin cytoskeleton, and VEGF signaling pathway. Our study created lasting value beyond molecular subtypes and underscored the significance of normal tissues in gastric cancer development, which drawn a novel prognostic model for gastric treatment.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":" ","pages":"5415758"},"PeriodicalIF":2.7,"publicationDate":"2022-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40620969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信